A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Olaparib (Primary) ; Trabectedin (Primary)
Indications Cholangiocarcinoma; Gynaecological cancer; Sarcoma; Solid tumours; Uveal melanoma
Focus Therapeutic Use
Acronyms NCT-PMO-1603; NCT-PMO1603 TOP-ART

25 Jan 2024 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Results assessing a composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort presented at the 48th European Society for Medical Oncology Congress.
28 Aug 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com